| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 06/24/2009 | CN100502889C Oral and dental composition |
| 06/24/2009 | CN100502888C Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative, potentially pathogenic gram-positive bacteria |
| 06/24/2009 | CN100502884C Re-epithelializing pharmaceutical compositions comprising xanthan gum |
| 06/24/2009 | CN100502882C Application of aescin and its derivative in preparing medicine for treating acute pulmonary inflammation |
| 06/24/2009 | CN100502875C Use of amitriptyline and / or berkomine in preparation of medicament for prophylaxis and treatment of infectious diseases |
| 06/24/2009 | CN100502873C Formulations containing cephalosporin |
| 06/24/2009 | CN100502863C 2,4,5-trisubstituded thiazolyl derivatives and their anti-inflammatory activity |
| 06/24/2009 | CN100502834C Amphotericin B structured emulsion |
| 06/23/2009 | USRE40794 Antibiotic product for therapy of infections; purification for improved purity and stability |
| 06/23/2009 | US7550582 labeled Peptide Nucleic Acid (PNA) derivatives which carry one or more phosphoryl radicals at the N terminus of the PNA backbone for fluorescence in-situ hybridization (FISH) detection; can be purified using chromatography or electrophoresis; use as pharmaceuticals and diagnostic agents |
| 06/23/2009 | US7550566 G-CSF conjugates |
| 06/23/2009 | US7550565 G-CSF conjugates |
| 06/23/2009 | US7550562 Having pathogenic activity that can induce pemphigus lesion; a peptide specifically recognized by the monoclonal antibody and useful as a therapeutic drug for pemphigus autoimmune disease; drug screening |
| 06/23/2009 | US7550480 1,8-naphthyridin-2(1H)-ones; treating CSBP/p38 kinase mediated diseases; cytokine suppressive anti-inflammatory drugs |
| 06/23/2009 | US7550442 For therapy of subject infected with a retrovirus |
| 06/23/2009 | US7550428 treating fungal infections; improved thermal stability and water solubility; releasing carbohydrate upon dispersion of the complex in water |
| 06/23/2009 | US7550285 Endotoxin binding lactic acid bacteria and bifidobacteria |
| 06/23/2009 | US7550147 Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA) |
| 06/23/2009 | US7550145 Adjuvant compositions |
| 06/23/2009 | US7550144 Antibody capable of reacting with cellular prion protein (PrP) ; for prevention of prion replication; for treatment or prevention of neuropathology such as Creutzfeldt-Jacob Disease |
| 06/23/2009 | US7550142 Anti-integrin antibodies, compositions, methods and uses |
| 06/23/2009 | US7550140 Stimulation of human T-cells and used to enhance antigen-specific immune responses; immunotherapy |
| 06/23/2009 | US7550139 Megasphaera elsdenii strain and its uses |
| 06/23/2009 | CA2492804C Novel inhibitors of kinases |
| 06/23/2009 | CA2459483C Plaster for the treatment of dysfunctions and disorders of nail growth |
| 06/23/2009 | CA2459400C Plaster for the treatment of dysfunctions and disorders of nails |
| 06/23/2009 | CA2430967C Remedies for bone marrow suppression and infectious diseases and white blood cell count elevating agents |
| 06/23/2009 | CA2402991C Drugs for the diagnosis of tissue-reproductive activity or the treatment of proliferative diseases |
| 06/23/2009 | CA2398620C Pyrazine derivatives, pharmaceutical compositions containing them, and intermediates therefor |
| 06/23/2009 | CA2389219C Dry powder compositions having improved dispersivity |
| 06/23/2009 | CA2362728C Improved aqueous solubility pharmaceutical formulations |
| 06/23/2009 | CA2337494C Herpes virus vectors for dendritic cells |
| 06/23/2009 | CA2336809C Water miscible macrolide solutions |
| 06/23/2009 | CA2163456C New procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis |
| 06/23/2009 | CA2139100C New sequences of hepatitis c virus genotypes and their use as therapeutic and diagnostic agents |
| 06/18/2009 | WO2009076397A2 Antiviral activity of cyclopentene nitro-ester and derivatives |
| 06/18/2009 | WO2009076321A2 Compositions and methods for modulating gene expression using asymmetrically-active precursor polynucleotides |
| 06/18/2009 | WO2009076243A2 Novel uses of chloramphenicol and analogues thereof |
| 06/18/2009 | WO2009076195A1 Treatment of drug-induced nausea with opioid antagonists |
| 06/18/2009 | WO2009076173A2 Fluorinated tripeptide hcv serine protease inhibitors |
| 06/18/2009 | WO2009076158A1 Compositions for inducing immune responses |
| 06/18/2009 | WO2009075826A1 Methods for increasing white blood cells |
| 06/18/2009 | WO2009075822A1 Methods for inhibiting t helper cell differentiation |
| 06/18/2009 | WO2009075776A1 Process for the preparation of retapamulin and its intermediates |
| 06/18/2009 | WO2009075583A1 Use of particles comprising an alcohol |
| 06/18/2009 | WO2009075323A1 Stable crystal of β-lactam compound |
| 06/18/2009 | WO2009075142A1 Bactericidal cleanser composition |
| 06/18/2009 | WO2009074812A1 Antibacterial condensed thiazoles |
| 06/18/2009 | WO2009074810A1 Antibacterial compositions |
| 06/18/2009 | WO2009074605A1 Aminothiazoles and their uses |
| 06/18/2009 | WO2009074305A1 Gold xanthogenates and medicaments comprising them |
| 06/18/2009 | WO2009074133A2 C-terminal ifapsoriasin fragments as antimicrobial peptides, the production thereof and use thereof |
| 06/18/2009 | WO2009073916A1 Improved treatment and prophylaxis |
| 06/18/2009 | WO2009049013A9 Cholera vaccines |
| 06/18/2009 | WO2009046864A3 Use of the human pancreatic polypeptide as a therapeutic agent |
| 06/18/2009 | WO2009046847A3 Use of peptide ll-37 as a therapeutic agent |
| 06/18/2009 | WO2009046846A3 Use of il-1 receptor peptide, alone or in combination with peptide ll-37, as a therapeutic agent |
| 06/18/2009 | WO2009043476A3 Neuromedin s as a therapeutic agent |
| 06/18/2009 | WO2009043448A3 Neuromedin u-25 and neuromedin s as therapeutic agents |
| 06/18/2009 | WO2009043440A3 Use of il-1 receptor peptide, alone or in combination with d-ala-gln-octadecyl ester, as a therapeutic agent |
| 06/18/2009 | WO2009025919A3 5-propargyl-pyrimidine derivatives as inhibitors of dihydrofolate reductase with antibacterial antiprotozoal, antifungal and anticancer properties |
| 06/18/2009 | WO2004070002A3 Cell lines and host nucleic acid sequences related to infectious disease |
| 06/18/2009 | US20090156684 Liquid antibacterial compositions incorporating trichlorocarbanilide with reduced water activity |
| 06/18/2009 | US20090156683 Fast release solid formulation, preparation and use thereof |
| 06/18/2009 | US20090156674 Valnemulin Salts with Organic Acids |
| 06/18/2009 | US20090156654 Derivative n-thiolated 2-oxazolidinone antibiotics |
| 06/18/2009 | US20090156645 Method for Increasing the Susceptibility of Peptide Deformylase Inhibitors by Using Efflux Pump Inhibitors |
| 06/18/2009 | US20090156638 Uses of nordihydroguaiaretic acid (NDGA) and derivatives thereof in preventing transmission of sexually transmitted diseases |
| 06/18/2009 | US20090156628 Aminothiazoles and their Uses |
| 06/18/2009 | US20090156621 Hcv inhibitors |
| 06/18/2009 | US20090156595 Pteridines useful as HCV inhibitors and methods for the preparation thereof |
| 06/18/2009 | US20090156574 N-(4-(5-Butyl-2-methoxyphenyl)-1,3-thiazol-2-yl)-4-((4-oxopiperidin-1-yl)carbonyl)benzamide; antiinflammatory, anticarcinogenic, antidiabetic, analgesic agents |
| 06/18/2009 | US20090156566 Method of treating middle ear infections |
| 06/18/2009 | US20090156545 Substituted Phosphate Esters of Nucleoside Phosphonates |
| 06/18/2009 | US20090156528 RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS C VIRUS (HCV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 06/18/2009 | US20090156527 Antiviral oligonucleotides targeting viral families |
| 06/18/2009 | US20090156517 Stable pharmaceutical compositions of aminoglycoside antibiotics, ion-chelating agents, and buffers |
| 06/18/2009 | US20090156512 potent activity against resistant pneumococci |
| 06/18/2009 | US20090156497 Non-cytotoxic PAP mutants |
| 06/18/2009 | US20090156484 Use of Transferrins for Treating Destructive Inflammation of Mucous Membrane |
| 06/18/2009 | US20090156483 Analogs of Ghrelin |
| 06/18/2009 | US20090155912 Method for transfer of molecular substances with prokaryontic nucleic acid-binding proteins |
| 06/18/2009 | US20090155887 Vaccine Composition |
| 06/18/2009 | US20090155845 Molecules designated LDCAM |
| 06/18/2009 | US20090155374 Bioactive agent, a low molecular weight chitosan, and a negatively charged third component; the chitosan dominates on the nanoparticle surface; enhanced permeability for paracellular drug delivery; chewable composition |
| 06/18/2009 | US20090155354 Dispensing encapsulated liquids into body cavities |
| 06/18/2009 | US20090155350 Chlamydia antigens and protein vaccine |
| 06/18/2009 | US20090155349 Methods of treating influenza viral infections |
| 06/18/2009 | US20090155339 Biocompatible Antimicrobial Filament Material |
| 06/18/2009 | US20090155335 Non-leaching non-fouling antimicrobial coatings |
| 06/18/2009 | US20090155313 Vaccine Against Salmonid Rickettsial Septicaemia Based on Arthrobacter Cells |
| 06/18/2009 | US20090155311 Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells |
| 06/18/2009 | US20090155309 Novel vaccine |
| 06/18/2009 | US20090155302 Antigen Arrays for Treatment of Allergic Eosinophilic Diseases |
| 06/18/2009 | US20090155298 Matrix Metalloproteinase 11 Vaccine |
| 06/18/2009 | US20090155281 Methods of using antibodies that bind both bcma and taci |
| 06/18/2009 | US20090155277 Use of immunesuppressant receptor |
| 06/18/2009 | US20090155270 Caspase inhibitors, especially caspase 3 inhibitors, for the treatment of influenza |
| 06/18/2009 | US20090155263 Compositions and methods for the treatment of immune related diseases |
| 06/18/2009 | US20090155250 Monoclonal antibodies against orthopoxviruses |